English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Acute myeloid leukemia (AML) is a genetically heterogeneous disease characterized by the accumulation of immature myeloid blasts in the bone marrow. While conventional chemotherapy usually results in initial reduction of leukemic blasts in the majority of patients, disease relapse is frequent, especially in elderly patients. Disease relapse is likely driven by leukemia stem cells that are not affected by chemotherapy and therefore retain their disease-initiating properties. Further characterization of this leukemia stem cell population is therefore highly relevant. In hematopoietic cells, the stage of differentiation and metabolic properties are closely linked. Hematopoietic stem cells characteristically have low levels of mitochondrial oxidative metabolism and consequently low levels of reactive oxygen species (ROS), which is relevant for

haematologica

CD34<sup>+</sup> acute myeloid leukemia cells with low levels of reactive oxygen species show increased expression of stemness genes and can be targeted by the BCL2 inhibitor venetoclax

CD34+ acute myeloid leukemia cells with low levels of reactive oxygen species show increased expression of stemness genes and can be targeted by the BCL2 inhibitor venetoclax

CD34⁺ acute myeloid leukemia cells with low levels of reactive oxygen species show increased expression of stemness genes and can be targeted by the BCL2 inhibitor venetoclax